Einsatz von Docetaxel oder Abirateron in Kombination mit einer Androgendeprivationstherapie beim metastasierten hormonnaiven Prostatakarzinom
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology
Link
http://link.springer.com/content/pdf/10.1007/s00120-019-0953-y.pdf
Reference46 articles.
1. Aggarwal R (2018) Abiraterone or Docetaxel plus androgen deprivation in hormone-sensitive prostate cancer: more questions than answers. Eur Urol 73:845–846
2. Albertsen PC, Klotz L, Tombal B et al (2014) Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol 65:565–573
3. Broder H, Gottlieb RA, Lepor NE (2008) Chemotherapy and cardiotoxicity. Rev Cardiovasc Med 9:75–83
4. Bryce AH, Chen YH, Liu G et al (2018) Patterns of PSA versus clinically progressive disease in the E3805 CHAARTED trial. J Clin Oncol. https://doi.org/10.1200/JCO.2017.75.3657
5. Clinton TN, Woldu SL, Raj GV (2017) Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. Expert Opin Pharmacother 18:825–832
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Overexpression of claspin promotes docetaxel resistance and is associated with prostate‐specific antigen recurrence in prostate cancer;Cancer Medicine;2021-07-09
2. Enoxacin Exerts Anti-Tumor Effects Against Prostate Cancer Through Inducing Apoptosis;Technology in Cancer Research & Treatment;2021-01-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3